Zhehan Shen

Zhehan Shen

Auto-generated profile, based on publicly available information

Zhehan Shen

Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in Medical Image Analysis
Verified
Journal Article
Closed access
FWFakai Wang
Fakai Wang
ZSZhehan Shen
Zhehan Shen
HLHuimin Lin
Huimin Lin
FYFuhua Yan
Fuhua Yan

2 October 2026 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
WLWanmin Liu
Wanmin Liu
ZSZhehan Shen
Zhehan Shen
LYLili Yang
Lili Yang
WZWenjie Zou
Wenjie Zou
YZYanyan Zhu
Yanyan Zhu
PWPeijun Wang
Peijun Wang
Accurate identification of aggressive tumor phenotypes remains a major challenge in hepatocellular carcinoma (HCC). Here, we developed and validated MAVEN (Multimodal Automated VETC Estimation Network), a fully automated multimodal deep learning system integrating magnetic resonance imaging (MRI), whole-slide histopathology images (WSIs), and clinical variables for predicting vessels encapsulating tumor clusters (VETC) and early recurrence risk. In this multicenter study including 1928 patients from five institutions, MAVEN demonstrated superior performance compared with unimodal and bimodal models, achieving an area under the curve (AUC) of 0.932 in the internal test cohort and 0.879-0.891 across four independent external cohorts. MAVEN-based risk stratification was significantly associated with early recurrence-free survival across all cohorts. Model explainability analyses revealed that both radiologic and histopathologic features contributed to prediction, with consistent spatial localization of high-risk regions. These findings suggest that multimodal integration enables robust and generalizable prediction of tumor aggressiveness and postoperative risk stratification.

1 November 2026 in Advanced Science
Verified
Journal Article
Open access
WXWei Xia
Wei Xia
ZSZhehan Shen
Zhehan Shen
MLMengsi Li
Mengsi Li
JLJianxin Lu
Jianxin Lu
JXJi Xia
Ji Xia
RLRuokun Li
Ruokun Li
Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide, with high recurrence rates following curative resection. Accurate non‐invasive assessment of tumor aggressiveness and recurrence risk is critical for surgical decision‐making and postoperative surveillance, yet remains challenging with conventional imaging modalities. Here, we developed a CT lesion foundation model (LFM), trained via self‐supervised learning on 32,120 generic lesion and 6,387 HCC‐specific CT patches to capture transferable intra‐lesional imaging phenotypes. Across one internal and two external validation cohorts, the sequentially pretrained LFM (LFM‐Seq) achieved area under the curve values of 0.916, 0.846, and 0.920 for microvascular invasion (MVI) assessment, and 0.833, 0.885 and 0.795 for pathological grade assessment. The model remained robust under scenarios of limited training data and tumor localization perturbations. Furthermore, LFM‐Seq‐derived risk scores stratified recurrence‐free survival (RFS), yielding an externally validated C‐index of 0.701, and remained independently associated with RFS after adjusting for clinicopathological factors. Exploratory biological interpretability analyses showed that LFM‐Seq‐derived risk phenotypes were associated with suppressed lymphocyte‐related immune programs. These results suggest that CT lesion foundation models can support non‐invasive and robust characterization of HCC aggressiveness, recurrence risk stratification and discovery of interpretable prognostic imaging biomarkers.

20 November 2026 in Medical Image Analysis
Verified
Journal Article
Closed access
SDShunjie Dong
Shunjie Dong
YPYulin Pu
Yulin Pu
ZSZhehan Shen
Zhehan Shen
XZXueyang Zou
Xueyang Zou
LDLin Deng
Lin Deng
RLRuokun Li
Ruokun Li

18 October 2026 in Advanced Science
Verified
Journal Article
Open access
ZSZhehan Shen
Zhehan Shen
WLWanmin Liu
Wanmin Liu
XLXiaoming Li
Xiaoming Li
WZWenjie Zou
Wenjie Zou
YLYiman Li
Yiman Li
PWPeijun Wang
Peijun Wang
Vessels encapsulating tumor clusters (VETC) are an aggressive vascular phenotype of hepatocellular carcinoma that is usually determined after surgery. A foundation model‐enabled framework for pathology‐informed VETC prediction on pretreatment magnetic resonance imaging (MRI), termed PIVOT, uses paired preoperative multiparametric MRI, postoperative hematoxylin and eosin whole‐slide images, and CD34 immunohistochemistry during model development, while inference requires only preoperative MRI. PIVOT‐MRI uses morphologic and vascular embedding alignment, and PIVOT‐Clinical combines the PIVOT‐MRI score with tumor size and alpha‐fetoprotein. The multicenter retrospective study includes 2052 patients in a training cohort, an internal test cohort, and four external validation cohorts. PIVOT‐MRI achieves an area under the receiver operating characteristic curve of 0.887 in the internal test cohort and 0.839‐0.861 across external cohorts. PIVOT‐Clinical increases the internal‐test area under the curve to 0.904 and PIVOT‐Clinical‐defined groups are associated with different two‐year recurrence risks. Removing both histopathologic alignment branches results in the largest ablation‐related performance decrease. Exploratory radiotranscriptomic analyses showed that higher PIVOT‐MRI scores were associated with angiogenesis‐related, endothelial, and proliferative transcriptional programs. PIVOT enables noninvasive preoperative assessment of pathology‐defined vascular aggressiveness in resectable hepatocellular carcinoma while preserving an MRI‐only clinical inference pathway.